

Gillian D Sanders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10577095/publications.pdf>

Version: 2024-02-01

80
papers

8,005
citations

101543

36
h-index

71685

76
g-index

82
all docs

82
docs citations

82
times ranked

10505
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence gaps in economic analyses of hearing healthcare: A systematic review. <i>EClinicalMedicine</i> , 2021, 35, 100872.	7.1	7
2	Right ventricular lead location and outcomes among patients with cardiac resynchronization therapy: A meta-analysis. <i>Progress in Cardiovascular Diseases</i> , 2021, 66, 53-60.	3.1	2
3	Abstract 9509: Is Left Ventricular Lead Placement at Site of Latest Mechanical Activation Associated with Cardiac Resynchronization Therapy Outcomes? Results of a Meta-Analysis. <i>Circulation</i> , 2021, 144, .	1.6	0
4	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2020, 223, 48-58.	2.7	13
5	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0219894.	2.5	10
6	Overview of Cost-effectiveness Analysis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1400.	7.4	71
7	When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?. <i>Cardiac Electrophysiology Clinics</i> , 2018, 10, 137-144.	1.7	11
8	How well does early-career investigators' cardiovascular outcomes research training align with funded outcomes research?. <i>American Heart Journal</i> , 2018, 196, 163-169.	2.7	4
9	Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins. <i>American Heart Journal</i> , 2018, 196, 131-143.	2.7	17
10	Training cardiovascular outcomes researchers: A survey of mentees and mentors to identify critical training gaps and needs. <i>American Heart Journal</i> , 2018, 196, 170-177.	2.7	0
11	Future Directions for Cost-effectiveness Analyses in Health and Medicine. <i>Medical Decision Making</i> , 2018, 38, 767-777.	2.4	58
12	Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2171-2187.	3.4	160
13	Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation. <i>Annals of Internal Medicine</i> , 2018, 169, 774.	3.9	17
14	Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 1031-1038.	7.1	24
15	Rheumatologists'™ knowledge of contraception, teratogens, and pregnancy risks. <i>Obstetric Medicine</i> , 2018, 11, 182-185.	1.1	13
16	Cost-Effectiveness Analysis 2.0. <i>New England Journal of Medicine</i> , 2017, 376, 203-205.	27.0	100
17	New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. <i>American Heart Journal</i> , 2017, 191, 21-29.	2.7	35
18	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy. <i>JAMA Cardiology</i> , 2017, 2, 685.	6.1	82

#	ARTICLE	IF	CITATIONS
19	Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease?. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	2.0	0
20	Implantable Cardioverter Defibrillators for Nonischemic Cardiomyopathy—Reply. <i>JAMA Cardiology</i> , 2017, 2, 1283.	6.1	0
21	Response to Letter Regarding Article, “Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women”. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	0
22	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1093.	7.4	2,149
23	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. <i>Circulation: Heart Failure</i> , 2016, 9, e002630.	3.9	28
24	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	4.1	30
25	Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 829-835.	0.7	59
26	Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. <i>Journal of General Internal Medicine</i> , 2015, 30, 1812-1820.	2.6	11
27	Benefits and Harms of Breast Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1615.	7.4	473
28	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review. <i>International Journal of Cardiology</i> , 2014, 177, 990-994.	1.7	14
29	Outcomes of Implantable Cardioverter-Defibrillator Use in Patients With Comorbidities. <i>JACC: Heart Failure</i> , 2014, 2, 623-629.	4.1	72
30	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	7.4	35
31	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 64, 32-39.	1.9	89
32	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-799.	4.8	45
33	Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?. <i>International Journal of Cardiology</i> , 2014, 172, 253-254.	1.7	4
34	Prioritization of Patient-Centered Comparative Effectiveness Research for Osteoarthritis. <i>Annals of Internal Medicine</i> , 2014, 160, 836.	3.9	29
35	Prioritization of Research Addressing Management Strategies for Ductal Carcinoma In Situ. <i>Annals of Internal Medicine</i> , 2014, 160, 484.	3.9	35
36	Performance measures to promote quality improvement in sudden cardiac arrest prevention and treatment. <i>American Heart Journal</i> , 2013, 165, 862-868.	2.7	11

#	ARTICLE	IF	CITATIONS
37	Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1931-1943.	2.5	287
38	Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: Does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials. <i>Heart Rhythm</i> , 2013, 10, 828-835.	0.7	13
39	Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 4188-4198.	1.6	221
40	Efficacy and Tolerability of Treatments for Chronic Cough. <i>Chest</i> , 2013, 144, 1827-1838.	0.8	36
41	Evaluating Cough Assessment Tools. <i>Chest</i> , 2013, 144, 1819-1826.	0.8	43
42	Priorities for Comparative Effectiveness Reviews in Cardiovascular Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 139-147.	2.2	7
43	Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2013, 122, 139-147.	2.4	202
44	Risk of Acute Thromboembolic Events With Oral Contraceptive Use. <i>Obstetrics and Gynecology</i> , 2013, 122, 380-389.	2.4	127
45	Assessment of the quality of existing patient educational tools focused on sudden cardiac arrest: a systematic evaluation by the Sudden Cardiac Arrest Thought Leadership Alliance. <i>Patient Preference and Adherence</i> , 2013, 7, 361.	1.8	6
46	Identifying Research Needs for Improving Health Care. <i>Annals of Internal Medicine</i> , 2012, 157, 439.	3.9	29
47	Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis. <i>PLoS ONE</i> , 2012, 7, e30194.	2.5	19
48	Systematic Review of the Incidence of Sudden Cardiac Death in the United States. <i>Journal of the American College of Cardiology</i> , 2011, 57, 794-801.	2.8	287
49	Potential Economic Viability of Two Proposed Rifampentine-Based Regimens for Treatment of Latent Tuberculosis Infection. <i>PLoS ONE</i> , 2011, 6, e22276.	2.5	20
50	Non-evidence-Based ICD Implantations in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 43.	7.4	207
51	Do Physicians' Attitudes toward Implantable Cardioverter Defibrillator Therapy Vary by Patient Age, Gender, or Race?. , 2011, 16, 77-84.		13
52	Development of an ovarian cancer screening decision model that incorporates disease heterogeneity. <i>Cancer</i> , 2011, 117, 545-553.	4.1	30
53	Cost-Effectiveness of Strategies to Improve HIV Testing and Receipt of Results: Economic Analysis of a Randomized Controlled Trial. <i>Journal of General Internal Medicine</i> , 2010, 25, 556-563.	2.6	43
54	Optimal Timing of Implantable Cardioverter-defibrillator Implantation After Myocardial Infarction: A Decision Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2010, 21, 791-798.	1.7	7

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of implantable cardioverter defibrillators in patients ≥65 years of age. <i>American Heart Journal</i> , 2010, 160, 122-131.	2.7	35
56	Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. <i>American Heart Journal</i> , 2010, 160, 605-618.e1.	2.7	21
57	Costs and Cost-effectiveness of Four Treatment Regimens for Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1055-1060.	5.6	86
58	Improving HIV Screening and Receipt of Results by Nurse-Initiated Streamlined Counseling and Rapid Testing. <i>Journal of General Internal Medicine</i> , 2008, 23, 800-807.	2.6	78
59	Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?. <i>Gynecologic Oncology</i> , 2008, 111, 179-187.	1.4	38
60	Preventing tomorrow's sudden cardiac death today. <i>American Heart Journal</i> , 2008, 156, 613-622.	2.7	46
61	Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis.. <i>European Journal of Endocrinology</i> , 2008, 158, 841-851.	3.7	99
62	Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age. <i>Annals of Internal Medicine</i> , 2008, 148, 889.	3.9	69
63	Prevalence of HIV Infection Among Inpatients and Outpatients in Department of Veterans Affairs Health Care Systems: Implications for Screening Programs for HIV. <i>American Journal of Public Health</i> , 2007, 97, 2173-2178.	2.7	37
64	HIV Testing of At Risk Patients in a Large Integrated Health Care System. <i>Journal of General Internal Medicine</i> , 2007, 22, 315-320.	2.6	22
65	Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. <i>Aids</i> , 2006, 20, 2207-2215.	2.2	60
66	Cost-effectiveness as an outcome in randomized clinical trials. <i>Clinical Trials</i> , 2006, 3, 543-551.	1.6	42
67	Evidence-Based Medicine And Policy: The Case Of The Implantable Cardioverter Defibrillator. <i>Health Affairs</i> , 2005, 24, 42-51.	5.2	33
68	Cost-Effectiveness of Implantable Cardioverter-Defibrillators. <i>New England Journal of Medicine</i> , 2005, 353, 1471-1480.	27.0	492
69	Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 2005, 352, 570-585.	27.0	552
70	Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: Randomized trial evidence through 2004. <i>American Heart Journal</i> , 2005, 149, 1020-1034.	2.7	59
71	Evaluating Human Papillomavirus Vaccination Programs. <i>Emerging Infectious Diseases</i> , 2004, 10, 1915-1923.	4.3	327
72	Cost-Effectiveness of the Implantable Cardioverter Defibrillator. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2003, 7, 479-482.	1.0	13

#	ARTICLE	IF	CITATIONS
73	Decision science and cervical cancer. <i>Cancer</i> , 2003, 98, 2003-2008.	4.1	15
74	Cost Effectiveness of a Potential Vaccine for <i>Human papillomavirus</i> . <i>Emerging Infectious Diseases</i> , 2003, 9, 37-48.	4.3	273
75	Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. <i>American Heart Journal</i> , 2002, 144, 440-448.	2.7	77
76	Evidence-based practice for mere mortals. <i>Journal of General Internal Medicine</i> , 2002, 17, 302-308.	2.6	30
77	Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2001, 135, 870.	3.9	70
78	Publishing web-based guidelines using interactive decision models. <i>Journal of Evaluation in Clinical Practice</i> , 2001, 7, 175-189.	1.8	19
79	Design and Pilot Evaluation of a System to Develop Computer-based Site-specific Practice Guidelines from Decision Models. <i>Medical Decision Making</i> , 2000, 20, 145-159.	2.4	25
80	Distributed Decision Support Using a Web-based Interface. <i>Medical Decision Making</i> , 1999, 19, 157-166.	2.4	27